O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.

Who mec for potential drug interactions

  • Entre para ver os comentários

  • Seja a primeira pessoa a gostar disto

Who mec for potential drug interactions

  1. 1. 7/20/2014 WHO MEC for potential drug interactions http://www.uptodate.com.myaccess.library.utoronto.ca/contents/image?imageKey=OBGYN%2F54244&rank=1~150&search=contracep%C3%A7%C3%A3o&source=image_view&view=print&topicKey=OBGYN/5459&source=se… 1/2 Official reprint from UpToDate®  www.uptodate.com ©2014 UpToDate® World Health Organization medical eligibility for contraceptive use: Drug interactions Condition COC CIC P/R POP DMPA NET­ EN LNG/ETG Implants Cu­IUD LNG­IUD Drugs which affect liver enzymes Rifampicin or rifabutin 3 2 3 3 DMPA 1 NET­EN 2 2 1 1 Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine) 3 2 3 3 DMPA 1 NET­EN 2 2 1 1 Lamotrigine 3 3 3 1 1 1 1 1 Antimicrobials (excluding rifampicin) Broad spectrum antibiotics 1 1 1 1 1 1 1 1 Antifungals and Antiparasites 1 1 1 1 1 1 1 1 Antiretroviral therapy Nucleoside reverse transcriptase inhibitors 1 1 1 1 DMPA 1 NET­EN 1 1 Initiation: 2/3 Continuation: 2 Initiation: 2/3 Continuation: 2
  2. 2. 7/20/2014 WHO MEC for potential drug interactions http://www.uptodate.com.myaccess.library.utoronto.ca/contents/image?imageKey=OBGYN%2F54244&rank=1~150&search=contracep%C3%A7%C3%A3o&source=image_view&view=print&topicKey=OBGYN/5459&source=se… 2/2 Non­nucleoside reverse transcriptase inhibitors 2 2 2 2 DMPA 1 NET­EN 2 2 Initiation: 2/3 Continuation: 2 Initiation: 2/3 Continuation: 2 Ritonavir­boosted protease inhibitors 3 3 3 3 DMPA 1 NET­EN 2 2 Initiation: 2/3 Continuation: 2 Initiation: 2/3 Continuation: 2 WHO comments: Although the interaction of rifampicin or rifabutin with POPs, NET­EN and LNG/ETG implants is not harmful to women, it is likely to reduce the effectiveness of POPs, NET­EN and LNG/ETG implants. Use of other contraceptives should be encouraged for women who are long­term users of any of these drugs.Whether increasing the hormone dose of POPs alleviates this concern remains unclear. Use of DMPA is a Category 1 because its effectiveness is not decreased by the use of rifampicin or rifabutin. 1: A condition for which there is no restriction for the use of the contraceptive method. 2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks. 3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method. 4: A condition which represents an unacceptable health risk if the contraceptive method is used. COC: low­dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen­only pill; DMPA: depot medroxyprogesterone acetate; NET­EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu­IUD: copper intrauterine device; LNG­IUD: levonorgestrel­releasing IUDs; E­IUD: copper­IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness­based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization. Reproduced with permission from: Medical Eligibility Criteria for Contraceptive Use ­ 3rd Ed. Available at: http://www.who.int/reproductive­ health/publications/mec/summary.html. Copyright ©2006 World Health Organization. Revised from: Medical Eligibility Criteria for Contraceptive Use, 2008 update. Available at: http://www.who.int/reproductive­health/publications/mec/. Graphic 54244 Version 2.0

×